重组人血小板生成素对比重组人白细胞介素-11治疗肺癌化疗后血小板减少的临床观察

Clinical Observation on Recombinant Human Thrombopoietin and Recombinant Human Interleukin-ll in the Treatment of Chemotherapy-induced Thrombocytopenia in Lung Cancer Patient

目的对比观察重组人血小板生成素（rhTPO）和重组人自细胞介素-11（rhIL．11）治疗非小细胞肺癌患者化疗所致血小板减少的疗效和安全性。方法选择2007年-2009年化疗后血小板计数〈75×109几的肺癌患者共40例，其中TPO组和IL-11组各20例，分别给予相应的治疗。结果化疗后TPO组和IL-11组的血小板计数最低值分别为（58．6±13．6）X109／L和（59．3±12．1）×10^9／L，两组差异无统计学意义；Ⅲ度以上血小板减少持续时间、血小板计数恢复至正常时间以及血小板计数恢复最高值，两组均有统计学差异；TPO组中有2例输注外源性血小板，IL-11组有4例（P〉0．05）TPO组和IL-11组不良反应发生率分别为10％和60％（P〈0．01）。结论对非小细胞肺癌化疗后血小板减少的患者，应用rhTPO治疗更安全有效。

Objective To evaluate the efficacy and safety of recombinant human thrombopoietin （rhTPO） and recombinant human interleukin-11 （rhIL-11） in the treatment of chemotherapy-induced thrombocytopenia in non- small cell lung cancer（NSCLC） patient.Methods From 2007 to 2009, forty NSCLC patients with platelet count 〈75 x 109/L after chemotherapy were enrolled into this study.They were randomly divided into two groups, TPO group and IL-11 group.They were administered by rhTPO and rhIL-11 respectively.Results The mean minimal platelet count after chemotherapy was （58.6 ± 13.6）× 10^9/L in TPO group versus （59.3 ＋ 12.1） x 109tL in IL-I 1 group（P〉0.05）.The duration of platelet count 〈50× 10^9/L and the time of platelet count recovering more than 100× 10^9/L in TPO group were both shorter than in IL-11 group.There was statistically significant difference in the mean maximal platelet count among the two groups.The patients receiving platelet transfusion were 2 in TPO group versus 4 in IL-11 group（P〉0.05）.The side-effect rate in TPO group was significantly lower than that in the IL-11 group（P〈0.01）.Conclusion Administration of rhTPO to deal with chemotherapy-induced thrombocytopenia in NSCLC patients can be more effective and safer than rhIL-11.